Skip to main content
. 2022 May 14;59(2):139–146. doi: 10.29399/npa.27793

Table 1.

Demographic and clinical data of subjects of the study

Study sample, n=150 n (%) or mean ± SD
Age (years), mean ± SD 14.7±1.6
Patients under the age of 15, n (%) 68 (45.3)
Sex, n (%)
 Male n (%) 69 (45.7)
 Female n (%) 81 (53.6)
Education, n (%)
 None 21 (14)
 Primary school 1 (0.7)
 Secondary school 50 (33.3)
 High school 78 (52)
Research diagnosis, n (%)
 PS 20 (13.3)
 PRS 59 (39.3)
 CC 71 (47.3)
DSM-5 diagnoses, n (%)
 Mood disorders 67 (44.7)
 Anxiety disorders 107 (71.3)
 Obsessive-compulsive disorders 20 (13.3)
 Attention-deficit hyperactivity disorders 63 (42.0)
 Post-traumatic stress disorder 10 (6.7)
 Other 60 (40)
Medications, n (%)
 Antidepressants 55 (36.7)
 Antipsychotics 44 (29.3)
 Sedatives/Hypnotics 28 (18.7)
 Mood stabilizers 6 (4)
 Other 25 (16.8)
Clinical Assessment, mean ± SD
 The total score of SOPS 45.78±21.91
 The total score of PANSS 77.32±24.32
 Global assessment of functioning 45.89±19.27
 Beck Depression Inventory 19.77±12.99

CC, clinical controls; DSM-5, the Diagnostic and Statistical Manual of Mental Disorders; GAF, global assessment of functioning; PANSS, the Positive and Negative Symptoms Scale; PRS, psychosis risk syndrome; PS, psychotic syndrome; SD, standard deviation; SOPS, the Scale of Prodromal Symptoms.